These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20031022)

  • 21. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
    Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
    Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial.
    Kotb MM; Hassan AM; AwadAllah AM
    Eur J Obstet Gynecol Reprod Biol; 2016 May; 200():11-5. PubMed ID: 26963897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
    Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
    Elgindy EA; El-Haieg DO; El-Sebaey A
    Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antral Follicle Diameter Variance Within Each Ovary May Be A Predictor For Poor Response In Cases With Normal Ovarian Reserve.
    Sanverdi I; Ozkaya E; Kucur SK; Bilen D; Eken MK; Bilgic BE
    Exp Clin Endocrinol Diabetes; 2018 Sep; 126(8):521-527. PubMed ID: 29388178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
    Cicek MN; Kahyaoglu I; Kahyaoglu S
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing the stimulation dose of rFHS in unexpected poor responders is not associated with better IVF outcome.
    Tutuncu L; Dundar O
    Ginekol Pol; 2012 Feb; 83(2):111-5. PubMed ID: 22568355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Protocol of GNRH antagonist in poor responders in IVF-ET cycles].
    Grzechocińska B; Fracki S; Marianowski P; Dworniak T; Bablok L; Marianowski L
    Ginekol Pol; 2003 Sep; 74(9):943-8. PubMed ID: 14674149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL; Couchman GM; Walmer DK
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve.
    Singh N; Zangmo R; Kumar S; Roy KK; Sharma JB; Malhotra N; Vanamail P
    Gynecol Endocrinol; 2013 Nov; 29(11):989-92. PubMed ID: 24004296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dehydroepiandrosterone on in vivo ovine follicular development.
    Narkwichean A; Jayaprakasan K; Maalouf WE; Hernandez-Medrano JH; Pincott-Allen C; Campbell BK
    Hum Reprod; 2014 Jan; 29(1):146-54. PubMed ID: 24256992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series.
    Casson PR; Lindsay MS; Pisarska MD; Carson SA; Buster JE
    Hum Reprod; 2000 Oct; 15(10):2129-32. PubMed ID: 11006185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.